Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17855805 | 0.97 | ALDH1A1 (0.32) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL17855794 | 0.97 | PIM3 (0.33) | MAPTSMN1; SMN2PIM3KDM4EMEN1 | |
| SCHEMBL17855910 | 0.97 | PIM3 (0.33) | MAPTSMN1; SMN2PIM3KDM4EMEN1 | |
| SCHEMBL17855884 | 0.97 | PIM3 (0.33) | MAPTSMN1; SMN2PIM3KDM4EMEN1 | |
| SCHEMBL17855806 | 0.97 | MAPT (0.34) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL17855792 | 0.97 | MAPT (0.34) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL17855704 | 0.96 | PIM3 (0.33) | MAPTSMN1; SMN2PIM3KDM4EMEN1 | |
| SCHEMBL17855847 | 0.95 | PIM3 (0.32) | MAPTSMN1; SMN2PIM3KDM4EMEN1 | |
| SCHEMBL17855689 | 0.95 | MAPT (0.34) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A | |
| SCHEMBL25814674 | 0.95 | PIM3 (0.34) | MAPTSMN1; SMN2ALDH1A1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160181525-A1 | COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20160181525-A1 | COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO., LTD. (JP) | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160181525-A1 | COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | ESR1, ESR2, CCNE2 | MAPT 1923/4885SMN1; SMN2 1358/4885ALDH1A1 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.